Dendritic cell-based immunotherapy for malignant lymphoma
10.3760/cma.j.issn.1009-9921.2009.08.024
- VernacularTitle:树突状细胞疫苗治疗恶性淋巴瘤的进展
- Author:
Li LIU
;
Zhenfang FAN
;
Xuejun ZHU
- Publication Type:Journal Article
- Keywords:
Lymphoma;
Dendritic cells;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2009;18(8):502-505
- CountryChina
- Language:Chinese
-
Abstract:
Due to therapeutic regimens for patients with malignant lymphoma (ML) is currently unsatisfactory, it is important to develop new complementary therapies for longer disease-free survival. Dendritic cells (DC) are specialized antigen-presenting cells of immune system and vaccination with tumor antigen-pulsed DC has been applied to treat patients for ML. In this review, we summarize various types of ML-associated antigens and clinical trials on DC-based immunotherapy in ML, and discuss the development of DC immunotherapy for ML patients in future.
